Skip to main content
Alligator Bioscience logo

Alligator Bioscience — Investor Relations & Filings

Ticker · ATORX ISIN · SE0024173637 LEI · 549300E15VI0MB7LXV19 ST Manufacturing
Open in API
Filings indexed 610 across all filing types
Latest filing 2018-03-22 Annual Report
Country SE Sweden
Listing ST ATORX

About Alligator Bioscience

https://alligatorbioscience.se/en/

Alligator Bioscience is a clinical-stage biotechnology company that develops tumor-directed immuno-oncology antibody drugs. The company's core strategy is to activate the patient's own immune system to fight cancer. It utilizes a proprietary technology platform for the discovery and development of novel antibody-based pharmaceuticals. The development pipeline features several drug candidates, including its lead asset mitazalimab, a CD40 agonist. The company specializes in creating therapeutics that are designed to be effective against various forms of cancer.

Recent filings

Filing Released Lang Actions
Annual Report 2017
Annual Report Classification · 1% confidence The document is explicitly titled '2017 ANNUAL REPORT' and contains comprehensive sections including an introduction, administration report, financial reports (income statement, balance sheet, cash flows), notes to the financial statements, and an auditor's report. It covers the full fiscal year 2017 and provides detailed business and financial performance data, fitting the definition of an Annual Report (10-K). FY 2017
2018-03-22 English
Notice of annual shareholders’ meeting in Alligator Bioscience AB (publ)
AGM Information Classification · 1% confidence The document is explicitly titled "Notice of annual shareholders' meeting in Alligator Bioscience AB (publ)". It details the date, time, location, requirements for participation (shareholder registration, proxy rules), and a detailed proposed agenda for the meeting. The agenda items cover the election of the Chairman, approval of reports, determination of remuneration, and resolutions on share issues and option programs. This content is characteristic of the official notice sent out prior to an Annual General Meeting (AGM). Therefore, the classification is AGM-R.
2018-03-22 English
Kallelse till årsstämma i Alligator Bioscience AB (publ)
AGM Information Classification · 1% confidence The document is titled "Kallelse till årsstämma i Alligator Bioscience AB (publ)" which translates to 'Notice of Annual General Meeting' in Swedish. It details the date, location, procedures for participation (registration, proxies), and presents a detailed agenda ('FÖRSLAG TILL DAGORDNING') covering items typical for an AGM, such as electing the chairman, approving financial statements, setting board/auditor fees, and proposing resolutions on remuneration policy, new share issues, and employee option programs. This content perfectly matches the definition of materials shared during an Annual General Meeting. Therefore, the classification is AGM-R.
2018-03-22 Swedish
Alligator Bioscience AB Bokslutskommuniké 2017
Earnings Release Classification · 1% confidence The document is titled "BOKSLUTSKOMMUNIKÉ JANUARI-DECEMBER 2017" (Year-End Report January-December 2017) and contains a detailed financial overview for the period October-December and January-December 2017, including key metrics like Net Sales, Operating Result, Net Income, and Earnings Per Share. It also includes a CEO commentary and a summary of the company's operations and project pipeline. This structure is characteristic of a comprehensive annual financial report, which corresponds to the Annual Report (10-K) definition, even though the document is in Swedish and might not be the official SEC Form 10-K filing itself, it serves the same informational purpose for the period. FY 2017
2018-02-16 Swedish
Alligator Bioscience AB Full Year Report 2017
Audit Report / Information Classification · 1% confidence The document is titled "FULL YEAR REPORT JANUARY-DECEMBER 2017" and contains extensive financial summaries for the period January-December 2017, including detailed tables with Net Sales, Operating Result, and Earnings per share. It also includes a CEO statement reflecting on the past year and outlook. This structure and content strongly indicate a comprehensive annual financial report. Although it is not explicitly labeled '10-K' (which is the SEC filing equivalent), in the context of general corporate filings, a 'Full Year Report' containing audited-style financial data and management commentary aligns best with the Annual Report category (10-K). Since the document is very long (93,914 characters) and contains the full report content, it is not an RPA or ER. FY 2017
2018-02-16 English
Earnings Release 2017
Earnings Release Classification · 1% confidence The document is titled "BOKSLUTSKOMMUNIKÉ JANUARI-DECEMBER 2017" (Year-End Report January-December 2017) and contains a detailed financial overview for the period October-December and January-December 2017, including key metrics like Net Sales, Operating Result, Net Income, and Earnings Per Share. It also includes a CEO commentary and a summary of the company's operations and project pipeline. This structure is characteristic of a comprehensive annual financial report, which corresponds to the Annual Report (10-K) definition, even though the document is in Swedish and might not be the official SEC Form 10-K filing itself, it serves the same informational purpose for the period. FY 2017
2018-02-16 Swedish

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.